The comparative study of the anti-inflammatory action of “Аrthritan” and the phytocomposition on its basis
Keywords:“Arthritan”, phytocomposition, anti-inflammatory effect, carrageenin inflammation, rats
According to the WHO expert estimates, 75 % of patients can be cured with the help of herbal remedies. Therefore, the future of modern medicine and pharmacy is associated with the integration of the evidence-based and natural medicine. The drug “Arthritan” manufactured by LLC “Zemna Green Planet” based on extracts of the medicinal plant raw material – willow bark, Echinacea flowers, birch leaves, elderberry flowers – is a promising drug for rheumatic diseases and potentially has the anti-inflammatory, analgesic, chondroprotective effects.
Aim. To study the anti-inflammatory properties of “Arthritan” and the phytocomposition based on it in order to substantiate its use in clinical practice as an anti-inflammatory, analgesic and chondroprotective agent.
Materials and methods. The anti-inflammatory effect of “Arthritan” and the phytocomposition based on it was studied on 50 white non-linear rats of both sexes using the carrageenan inflammation model.
Results. On the model of exudative inflammation of the extremities in rats the drugs “Arthritan”, “Nephrolik” and the phytocomposition exhibit a moderate level of the anti-inflammatory effect, which is the most pronounced when using the phytocomposition and reaches 29.2 %. Under the effect of “Nevrin” the anti-inflammatory action is statistically insignificant or weakly expressed and reaches the maximum of 14.7 %, which does not have pharmacological significance since the level of the pharmacological activity of at least 20 % is significant for the experimental study of anti-inflammatory and / or analgesic agents. This allows us to conclude that the basis of the relatively high anti-inflammatory activity of the phytocomposition is the summation of the pharmacological effects of “Arthritan” and “Nephrolik”, and the contribution to the final level of activity of the research combination of “Nevrin” is insignificant.
Conclusions. In the course of studying the anti-inflammatory properties of the drugs under research on the model carrageenin inflammation of the rat’s foot the anti-exudative effect of various severity was found, which amounted to 19.8 % for “Arthritan”, for “Nevrin” – 14.7 %, “Nephrolik” – 21.0 % and their combinations – 29.2 %. By the level of its anti-inflammatory activity the phytocomposition studied significantly exceeds the activity of its components. It is based on the summation of the pharmacological effects of “Arthritan” and “Nephrolik”, while the contribution to the final level of activity of “Nevrin” is insignificant.
Harna, S. V., Vladymyrova, I. M., Burd, N. B., Heorhiiants, V. A., Kotov, A. H., Prokopenko, T. S., ... Vasylieva, O. A. (2016). Suchasna fitoterapiia: navchalnyi posibnyk. Kharkiv: «Drukarnia Madryd», 580.
Harnyk, T. P., Tumanov, V. A., Pokanevych, V. V., Frolov, V. M., Peresadin, M. O. (2012). Fitoterapiia. Chasopys, 1, 4–11.
Bone K., Mills, S. (2012). Principles and Practice of Phytotherapy: Modern Herbal Medicine. Hardbound, 1056.
Heinrich, M. (2012). Fundamentals of Pharmacognosy and Phytotherapy. UK: Elsevier Health Sciences, 336.
Kunle, O. F., Egharevba, H. O., Ahmadu, P. O. (2012). Standardization of herbal medicines: A review. Int. J. Biodivers. Conserv., 4(3), 101–112. https://doi.org/10.5897/ijbc11.163
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n.d.). Available at: http://www.drlz.kiev.ua/
Guide for the care and use of laboratory animals, 8th edition. (2011). Washington: The National Academies Press, 246.
European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe. (1986). Strasbourg, 52.
Stephanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennykh sredstv. Kyiv: Avitcena, 528.
Trukhacheva, N. V. (2012). Matematicheskaia statistika v mediko–biologicheskikh issledovaniiakh s primeneniem paketa Statistica. Moscow: GEOTAR–Media, 379.
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).